Cyberonics and the Implantable Vagus Nerve Stimulator: History, Technology, and Clinical Evidence

The implantable vagus nerve stimulator is the longest-running neuromodulation therapy targeting the vagus nerve, with over 125,000 devices implanted worldwide since the mid-1990s. The company behind it — originally Cyberonics, now LivaNova — built an entire therapeutic category around a single idea: that pulsed electrical stimulation of the left cervical vagus nerve could alter brain activity enough to control seizures and lift treatment-resistant depression. Three decades of clinical data now show where that idea delivered and where it fell short.

From Concept to Company: The Origins of Cyberonics

The idea of stimulating the vagus nerve to treat neurological conditions emerged from the work of Jacob Zabara, a neurophysiologist at Temple University, in the early 1980s. Zabara demonstrated in animal models that electrical stimulation of the cervical vagus nerve could terminate experimentally induced seizures. His work attracted the attention of Reese Terry, an entrepreneur and engineer, who founded Cyberonics, Inc. in 1987 in Houston, Texas, specifically to commercialise the concept.

The company’s first human implant occurred in 1988. Early clinical trials through the 1990s — the E03 and E05 pivotal studies — tested the device in patients with medically refractory partial-onset seizures who had failed multiple anticonvulsant medications. The E05 trial, a randomised controlled study comparing high-stimulation to low-stimulation parameters, demonstrated a median 28% seizure reduction in the high-stimulation group versus 15% in the low-stimulation group at 3 months.

How the Implantable VNS Works

The VNS Therapy System consists of a pulse generator — roughly the size of a stopwatch — implanted subcutaneously in the left chest wall, below the clavicle. A lead wire tunnels under the skin to the left cervical vagus nerve in the neck, where helical electrodes wrap around the nerve without penetrating it.

Standard parameters deliver 30-second bursts of electrical current (typically 0.25–3.0 mA, 20–30 Hz, 250–500 microsecond pulse width) every 5 minutes. The stimulation activates afferent vagal A and B fibres that project to the nucleus tractus solitarius (NTS) in the brainstem. From the NTS, signals propagate to the locus coeruleus, raphe nuclei, thalamus, and widespread cortical regions — modulating noradrenergic and serotonergic neurotransmission, which are the pathways implicated in both seizure suppression and mood regulation.

The device is programmed and adjusted externally by a clinician using a handheld wand communicating via telemetry. Patients can also use a handheld magnet to trigger an additional burst of stimulation when they sense an oncoming seizure (magnet mode), or to temporarily inhibit stimulation if side effects become uncomfortable.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

FDA Approvals and Regulatory Milestones

The US Food and Drug Administration approved VNS Therapy for refractory epilepsy in 1997, making it the first FDA-approved device-based therapy for epilepsy since the approval of brain surgery itself. This was a premarket approval (PMA), the most rigorous FDA regulatory pathway, based on the E03 and E05 trial data.

In 2005, the FDA approved VNS Therapy for treatment-resistant depression (TRD) — defined as failure of at least four adequate antidepressant trials. This approval was controversial: the D-02 acute pivotal trial did not meet its primary endpoint (no statistically significant difference from sham at 10 weeks). The FDA granted approval based partly on an open-label registry (D-04) showing sustained response rates increasing over 12–24 months, arguing that VNS for depression requires longer exposure than the acute trial captured.

The European CE mark was granted earlier, in 1994 for epilepsy, and subsequently for depression and other indications. This broader regulatory environment in Europe allowed earlier clinical adoption and the accumulation of long-term observational data.

Device Evolution: NCP Through SenTiva

The original device was the NeuroCybernetic Prosthesis (NCP), Model 100. Subsequent generations improved battery life, reduced device size, and added programmable features:

AspireSR (2015) introduced the first closed-loop feature for VNS. A cardiac sensor detected ictal tachycardia — the heart-rate spike that accompanies many seizures — and automatically triggered stimulation without requiring the patient or a magnet. This represented a conceptual shift from scheduled, open-loop stimulation to responsive, event-driven therapy.

SenTiva (2017) further reduced the generator size by roughly 40% compared to the AspireSR, improved battery longevity, and added programming flexibility with day/night scheduling. Clinicians could programme different stimulation intensities for sleep versus waking hours, acknowledging that seizure patterns and tolerability differ across the circadian cycle.

Battery life across generations ranges from approximately 3 to 8 years depending on stimulation parameters, after which the generator must be surgically replaced. The lead typically remains in place and is connected to the new generator.

Clinical Evidence in Epilepsy

The evidence base for VNS in epilepsy has grown substantially since the pivotal trials. A consistent finding across studies is that efficacy improves over time — the so-called “progressive benefit” phenomenon. While the E05 trial showed 28% median seizure reduction at 3 months, long-term registries report 50% or greater seizure reduction in roughly half of patients by 2–3 years of continuous therapy.

A 2023 Cochrane systematic review of randomised evidence confirmed that high-level VNS is more effective than low-level (sham-like) stimulation for seizure reduction, though the overall quality of evidence remained moderate. A meta-analysis published in Epilepsia in 2022, encompassing over 5,500 patients from 78 studies, reported a 50% responder rate (patients achieving at least 50% seizure reduction) of approximately 50.6% with a mean follow-up exceeding 12 months.

VNS does not typically eliminate seizures entirely. Complete seizure freedom occurs in only 5–8% of implanted patients. It is positioned as adjunctive therapy for patients who are not candidates for resective epilepsy surgery or who have failed surgery, not as a first-line treatment. Predictors of better response remain poorly defined, though some studies suggest that generalised epilepsy syndromes, lower pre-implant seizure frequency, and shorter duration of epilepsy correlate with better outcomes.

Clinical Evidence in Depression

The depression indication remains the more debated application. As noted, the acute pivotal trial failed its primary endpoint. Subsequent data supporting VNS in TRD came primarily from open-label registries comparing VNS-plus-treatment-as-usual (TAU) against TAU alone.

The RESTORE trial, a large real-world registry, reported that by 5 years, cumulative response rates (at least 50% improvement in Montgomery-Asberg Depression Rating Scale) reached approximately 68% in the VNS+TAU group versus 41% in TAU alone. Remission rates showed a similar gap. These data suggest that VNS for depression requires patience — meaningful benefit often takes 6–12 months to emerge, with continued improvement over years.

Critics note that unblinded registries cannot adequately control for placebo effects, regression to the mean, or the clinical attention that accompanies device implantation and regular programming visits. Proponents counter that the durability of response over 5+ years is difficult to attribute to placebo alone, and that conventional antidepressant trials rarely demonstrate sustained benefit at that timescale in TRD populations.

From Cyberonics to LivaNova

In 2015, Cyberonics merged with Sorin Group, an Italian cardiac surgery and cardiac rhythm management company, to form LivaNova PLC, headquartered in London. The merger combined Cyberonics’ neuromodulation portfolio with Sorin’s cardiovascular devices. LivaNova continues to manufacture and market VNS Therapy as its core neuromodulation product.

The company has expanded research into additional VNS indications including heart failure (the ANTHEM-HFrEF programme), where cervical VNS is being studied for its potential to modulate autonomic imbalance and reduce inflammatory markers. Early-phase results showed improvements in cardiac function metrics and quality of life, but definitive Phase III data are still awaited.

Surgery, Side Effects, and Practical Considerations

Implantation is typically performed as an outpatient procedure under general anaesthesia, lasting 1–2 hours. The surgeon makes two small incisions — one in the neck to access the left vagus nerve and one below the left clavicle for the generator pocket. Serious surgical complications are uncommon: infection rates are approximately 3–6%, and vocal cord paresis from nerve manipulation occurs in 1–2% of cases, usually resolving within weeks.

The most common side effects are stimulation-related: hoarseness or voice alteration during the “on” period (reported by up to 60% of patients initially, though most habituate), throat tingling, cough, and mild dyspnoea. These are parameter-dependent and typically manageable by adjusting stimulation intensity, pulse width, or duty cycle. Side effects during the “off” period are minimal, which distinguishes VNS from systemic medications that produce continuous side effects.

Cost is substantial. In the US, the device, surgery, and initial programming typically total $20,000–$40,000. Insurance coverage varies; most commercial insurers and Medicare cover VNS for epilepsy when medical necessity criteria are met. Coverage for depression remains inconsistent, reflecting the ongoing debate about the strength of the evidence base.

VNS in Context: Where Implantable Stimulation Fits Today

The implantable VNS occupies a specific niche: it is the established option for patients with medically refractory epilepsy who are not surgical candidates, and it is one of a small number of device-based options for treatment-resistant depression alongside deep brain stimulation and electroconvulsive therapy. It is not a consumer device, not available over the counter, and requires a neurosurgeon or epileptologist for implantation and ongoing management.

For those exploring non-invasive vagus nerve stimulation — transcutaneous auricular VNS (taVNS) devices that stimulate the ear’s vagal branch without surgery — the evidence base, mechanisms, and clinical context are different. Those are covered in our guide to vagus nerve stimulation at home.

Want a clear, science-backed overview of how the vagus nerve shapes your health — from heart rate and digestion to mood and immunity? Get My Vagus Nerve & Me eBook and understand the nerve that connects brain to body.